PLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Protalix BioTherapeutics's share price is $1.21. Protalix BioTherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Protalix BioTherapeutics's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Protalix BioTherapeutics was 2.34. The lowest was 0.88. And the median was 1.95.
As of today (2024-04-25), Protalix BioTherapeutics's share price is $1.21. Protalix BioTherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.02. Therefore, Protalix BioTherapeutics's PE Ratio for today is 60.50.
As of today (2024-04-25), Protalix BioTherapeutics's share price is $1.21. Protalix BioTherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $0.02. Therefore, Protalix BioTherapeutics's PE Ratio without NRI for today is 60.50.
During the past 13 years, Protalix BioTherapeutics's highest PE Ratio without NRI was 100.00. The lowest was 26.80. And the median was 73.00.
The historical data trend for Protalix BioTherapeutics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Protalix BioTherapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Protalix BioTherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Protalix BioTherapeutics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 1.21 | / | -0.02 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (AMEX:PLX) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Protalix BioTherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Dror Bashan | director, officer: President and CEO | 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100 |
Eliot Forster | director | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Aharon Schwartz | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
Zvi Shmuel Ben | director | 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401 |
Dexcel Pharma Technologies Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 3060000 |
Dan Oren | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Eyal Rubin | officer: Sr. VP and CFO | C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601 |
Yaron Naos | officer: Sr. VP, Operations | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
Yael Hayon | officer: Vice President, R&D | 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401 |
Zeev Bronfeld | director | 6 URI STREET, TEL AVIV L3 64954 |
Amos Bar-shalev | director | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
David Granot | director | 6225 NEIL ROAD, RENO NV 89511 |
Pol F Boudes | director | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Moshe Manor | officer: President & CEO | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100 |
From GuruFocus
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 12-04-2022
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire PRNewswire • 11-07-2022
By PRNewswire PRNewswire • 02-24-2023
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire • 07-31-2023
By PRNewswire • 08-07-2023
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire PRNewswire • 12-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.